$29.66
-1.83 (-5.81%)
Performance
1D
—
1W
-4.38%
1M
-1.59%
3M
-28.58%
6M
-13.02%
1Y
+101.49%
YTD
-14.62%
Open$31.38
Previous Close$31.49
Day High$31.42
Day Low$29.16
52W High$43.73
52W Low$13.78
Volume—
Avg Volume2.00M
Market Cap5.35B
P/E Ratio—
EPS$-2.44
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$32.08
Below
SMA 200
$35.58
Below
RSI (14)
62.3
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
18 analysts
Price Target
+183.1% upside
Current
$29.66
$29.66
Target
$83.97
$83.97
$51.90
$83.97 avg
$108.57
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.66B | 1.76B | 1.56B |
| Net Income | -282,006,496 | -354,880,166 | -268,142,716 |
| Profit Margin | -17.0% | -20.2% | -17.2% |
| EBITDA | -474,772,680 | -496,954,417 | -453,512,070 |
| Free Cash Flow | -249,995,996 | -301,722,393 | -268,935,506 |
| Rev Growth | -0.8% | +1.9% | -1.2% |
| Debt/Equity | 0.59 | 0.54 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |